Invesaro

Stocks Comparison

Intellia Therapeutics vs Alpha Teknova: revenue, profit, margins and growth compared

Intellia Therapeutics brought in $67.7M of revenue in fiscal 2025, Alpha Teknova $40.5M in fiscal 2025. Revenue changed by +16.9% at Intellia Therapeutics and +7.4% at Alpha Teknova on the year before, so Intellia Therapeutics grew faster. Intellia Therapeutics kept -609.9% of its revenue as net profit, Alpha Teknova -42.6%. Free cash flow was -$395.9M at Intellia Therapeutics and -$9.8M at Alpha Teknova.

Side by side, latest fiscal year

NTLATKNO
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$67.7M$40.5M
Revenue growth+16.9%+7.4%
Net income-$412.7M-$17.3M
Net margin-609.9%-42.6%
Free cash flow-$395.9M-$9.8M
Free cash flow margin-585.0%-24.2%
Earnings per share (diluted)-$3.81-$0.32
Cash$155.5M$5.9M
Debtn/a$13.1M
Price to earningsn/an/a
Market value$1.6B$500.9M
Dividend yieldn/an/a
Rank by revenue in sector#339 of 523 · Health care#376 of 523 · Health care

Over the years

Revenue
NTLA FY2018: $30.4MNTLA FY2019: $43.1MNTLA FY2020: $58MNTLA FY2021: $33.1MNTLA FY2022: $52.1MNTLA FY2023: $36.3MNTLA FY2024: $57.9MNTLA FY2025: $67.7MTKNO FY2021: $31.3MTKNO FY2021: $36.9MTKNO FY2022: $41.4MTKNO FY2023: $36.7MTKNO FY2024: $37.7MTKNO FY2025: $40.5MFY18FY19FY20FY21FY22FY23FY24FY25
NTLA $67.7MTKNO $40.5M
Net income
NTLA FY2018: -$85.3MNTLA FY2019: -$474.2MNTLA FY2020: -$134.2MNTLA FY2021: -$267.9MNTLA FY2022: -$474.2MNTLA FY2023: -$481.2MNTLA FY2024: -$519MNTLA FY2025: -$412.7MTKNO FY2021: $3.6MTKNO FY2021: -$9.8MTKNO FY2022: -$47.5MTKNO FY2023: -$36.8MTKNO FY2024: -$26.7MTKNO FY2025: -$17.3MFY18FY19FY20FY21FY22FY23FY24FY25
NTLA -$412.7MTKNO -$17.3M
Net margin
NTLA FY2018: -280.4%NTLA FY2019: -1,100.1%NTLA FY2020: -231.5%NTLA FY2021: -810.5%NTLA FY2022: -909.8%NTLA FY2023: -1,326.5%NTLA FY2024: -896.8%NTLA FY2025: -609.9%TKNO FY2021: 11.4%TKNO FY2021: -26.6%TKNO FY2022: -114.6%TKNO FY2023: -100.3%TKNO FY2024: -70.9%TKNO FY2025: -42.6%FY18FY19FY20FY21FY22FY23FY24FY25
NTLA -609.9%TKNO -42.6%
Revenue growth
NTLA FY2019: +41.6%NTLA FY2020: +34.5%NTLA FY2021: -43.0%NTLA FY2022: +57.7%NTLA FY2023: -30.4%NTLA FY2024: +59.6%NTLA FY2025: +16.9%TKNO FY2021: +17.9%TKNO FY2022: +12.3%TKNO FY2023: -11.4%TKNO FY2024: +2.9%TKNO FY2025: +7.4%FY19FY20FY21FY22FY23FY24FY25
NTLA +16.9%TKNO +7.4%
Free cash flow
NTLA FY2018: -$67.6MNTLA FY2019: -$110MNTLA FY2020: -$53.5MNTLA FY2021: -$237.8MNTLA FY2022: -$346.8MNTLA FY2023: -$408.1MNTLA FY2024: -$354.7MNTLA FY2025: -$395.9MTKNO FY2021: -$3MTKNO FY2021: -$28.9MTKNO FY2022: -$55.5MTKNO FY2023: -$26.7MTKNO FY2024: -$13.5MTKNO FY2025: -$9.8MFY18FY19FY20FY21FY22FY23FY24FY25
NTLA -$395.9MTKNO -$9.8M

Fiscal years as each company reports them; the two may end in different months.

Questions about Intellia Therapeutics and Alpha Teknova

Which is bigger by revenue, Intellia Therapeutics or Alpha Teknova?

Intellia Therapeutics is bigger by revenue: $67.7M in fiscal 2025, against $40.5M for Alpha Teknova in fiscal 2025.

Which keeps more of its revenue as profit, Intellia Therapeutics or Alpha Teknova?

Intellia Therapeutics had a net margin of -609.9% in fiscal 2025; Alpha Teknova had -42.6% in fiscal 2025.

Which grew revenue faster, Intellia Therapeutics or Alpha Teknova?

In their latest fiscal years revenue changed by +16.9% at Intellia Therapeutics and +7.4% at Alpha Teknova.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies